19th Annual Conference - Poster Presentations: HIV Treatment and Pharmacokinetics (P135 - P163)

P135 SPIRIT: Switching to rilpivirine/emtricitabine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48 regardless of viral load or CD4 + count prior to initiation of ARV therapy
E Wilkins1, M Fisher2, F Palella3, P Tebas4, B Gazzard5, P Ruane6, J Van Lunzen7, D Shamblaw8, J Flamm9, R Ebrahimi10, K White10, W Guyer10, D Porter10, A Smith11 and T Fralich10
1North Manchester General Hospital, Manchester, UK, 2Brighton and Sussex University Hospital, Brighton, UK, 3Northwestern University, Chicago, USA, 4University of Pennsylvania, Philadelphia, USA, 5Chelsea and Westminster Hospital, London, UK, 6Peter J Ruane MD Inc, Los Angeles, USA, 7ID Unit University Medical Centre, Hamburg, Germany, 8La Playa Medical Group, San Diego, USA, 9Kaiser Permanente, Sacramento, USA, 10Gilead Sciences, Foster City, USA and 11Gilead Sciences, Cambridge, UK

P136 STaR Study: Single tablet regimen rilpivirine/emtricitabine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adults regardless of baseline viral load and CD4 + count
E Wilkins1, C Cohen2, D Wohl3, J Arribas4, K Henry5, J Van Lunzen6, M Bloch7, W Towner8, H Wang9, D Porter9, S De-Oertel9, K Aizen10 and T Fralich9
1North Manchester General Hospital, Manchester, UK, 2Community Research Initiative of New England, Boston, USA, 3University of North Carolina at Chapel Hill, North Carolina, USA, 4Hospital La Paz, Madrid, Spain, 5HIV Program Hennepin County Medical Center, Minneapolis, USA, 6Infectious Disease Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 7Holdsworth House Medical Practice, Sydney, Australia, 8Kaiser Los Angeles Medical Center, Los Angeles, USA, 9Gilead Sciences, Foster City, USA and 10Gilead Sciences, Cambridge, UK

P137 Efficacy and Safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF from an integrated analysis of Phase 2 and 3 clinical trials
M Fisher1, D Ward2, G Crowfoot3, D Shamblaw4, N Bellos5, S Chen6, M Rhee6, K Aizen7 and J Szwarcberg6
1Brighton and Sussex University Hospital, Brighton, UK, 2Du Pont Circle Physicians Group, Washington DC, USA, 3G Crowfoot, Houston, USA, 4La Playa Medical Group, San Diego, USA, 5South West Infectious Disease Inc, Dallas, USA, 6Gilead Sciences, Foster City, USA and 7 Gilead Sciences, Cambridge, UK

P138 Patient and physician preferences regarding medications for HIV treatment
A Lloyd1, D Collomb2, S Hearn1, S Ali1 and F Mughal3
1Oxford Outcomes, Oxford, UK, 2AstraZeneca, Luton, UK and 3AbbVie Ltd, Maidenhead, UK

P139 Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naïve HIV-1-infected patients
C Orkin1, J Rockstroh2, E DeJesus3, K Henry4, J Molina5, J Gathe6, X Wei7, M Fordyce7, M Rhee7, A Smith8 and J Szwarcberg7
1St Bartholomew's Hospital, London, UK, 2University of Bonn, Bonn, Germany, 3Orlando Immunology Center, Orlando, USA, 4Hennepin County Medical Center, Minneapolis, USA, 5St Louis Hospital, Paris, France, 6Therapeutic Concepts P. A., Houston, USA, 7Gilead Sciences, Foster City, USA and 8Gilead Sciences, Cambridge, UK

P140 Nevirapine use in a large multi-ethnic South London HIV cohort
R Brum1, E Mabonga1, R Rajani2, C Taylor1 and E Cheserem1
1King's College Hospital, London, UK and 2Guy's and St Thomas' Hospital, London, U.K.

P141 Switching to rilpivirine in clinical practice: experience of two London HIV units
N Marshall1, L Hedley2, L Swaden1, C Smith3, N Brima2, R Tsintas1, P Benn2, M Tyrer1, L Waters2, S Edwards2 and M Johnson1
1Royal Free London NHS Foundation Trust, London, UK, 2Mortimer Market Centre, NHS Camden Provider Services, London, UK and 3University College London, London, UK

P142 Use of antacid preparations with HAART
T Constandinou1, S Vekeria2, GKJ Singh2, M Bower2 and M Nelson2
1Imperial College School of Medicine, London, UK and 2Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

P143 Abstract withdrawn

P144 HLA B*5701 positivity, disease status and response to combination antiretroviral therapy (cART) in the UK Collaborative HIV Cohort (CHIC) study
S Jose1, C Sabin1, C Leen2 and D Chadwick3, for the UK CHIC Study
1University College London, London, UK, 2University of Edinburgh, Edinburgh, UK and 3James Cook University Hospital, Middlesbrough, UK

P145 Long-term therapeutic success of etravirine in switch and naïve patients
L Bull, M Bower and M Nelson
Chelsea and Westminster Hospital, London, UK

P146 Real-life clinical experience with Eviplera™
A Gothard, E Wilkins and A Ustianowski
Infectious Diseases Unit, North Manchester General Hospital, Manchester, UK

P147 Rilpivirine in clinical practice
H Alexander1, K Seneviratne2, Y Kamuntu1, C Richardson2, Y Gilleece2, A de Ruiter1 and A Teague1
1Guy's and St Thomas' NHS Trust, London, UK and 2Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

P148 Safety and efficacy of rilpivirine-tenofovir-emtricitabine in treatment-experienced patients infected with HIV-1
M Cevik1, L Guy2, S Sonecha1 and M Nelson1
1Chelsea and Westminster Hospital, London, UK and 2Imperial College Hospital, London, UK

P149 Five years of experience with raltegravir in a large HIV centre
C van Halsema1, T Whitfield1, N Lin2, K Millington1, A Thompson1, A Gothard1 and A Ustianowski1
1North Manchester General Hospital, Manchester, UK and 2Manchester Medical School, Manchester, UK

P150 Treatment change within 12 months of starting highly active antiretroviral therapy (HAART) in HIV-positive therapy-naïve patients
M McNulty, J Leighton, L McFarlane and A Ustianowski
North Manchester General Hospital, Manchester, UK

P151 The use of dual maraviroc/ritonavir-boosted darunavir combination in clinical practice
V Vishwanath1, GKJ Singh2, S Dub1, M Bower2 and M Nelson2
1Imperial College School of Medicine, London, UK and 2Chelsea and Westminster Hospital, London, UK

P152 Newly licensed darunavir suspension: clinical experiences
C Okoli, K Khonyongwa, J Ainsworth, A Schwenk and C Wood
North Middlesex University Hospital NHS Trust, London, UK

P153 Salvage therapy with protease inhibitor-sparing regimens containing etravirine
L Bull, M Bower and M Nelson
Chelsea and Westminster Hospital, London, UK

P154 Re-audit: Late presentation of HIV-positive patients in a small city in the UK
N Dean, S Cherif and K Yoganathan
Singleton Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, UK

P155 Dual antiretroviral therapy in a treatment-experienced HIV cohort
H Wiggins1, N Ahmed2, P Benn2, S Edwards2 and L Waters2
1Watford General Hospital, Watford, UK and 2Mortimer Market Centre, London, UK

P156 Eviplera® 1 year on: experience of a large teaching hospital
M Phillips, C Saxon, B McBrien and G Schembri
Central Manchester NHS Foundation Trust, Manchester, UK

P157 Indications for changing to raltegravir therapy in patients with a pre-existing undetectable viral load
V Van-de-Velde, M Nelson, M Bower and S Sonecha
Chelsea and Westminster Hospital, London, UK

P158 Systematic review of existing evidence on the costs and cost-effectiveness of interventions to enhance uptake and adherence to antiretroviral therapy
IP Molosankwe1, S Byford1, P McCrone1 and R Horne2
1King's College London, London, UK and 2University College London, London, UK

P159 Antiretroviral absorption after biliopancreatic diversionduodenal switch: a case report
J Beale and S Andrews
Farnham Road Clinic, Guildford, UK

P160 Zidovudine: going, going, gone?
L Johnson, A Teasdale, N Sithamparanathan, P Hine and E Wilkins
North Manchester General Hospital, Manchester, UK

P161 Clinical audit: Initiation of antiretroviral treatment regimen in a small city HIV clinic during 2011 and 2012
S Cherif, C Williams, S Danino and K Yoganathan
Singleton Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, UK

P162 Clinical outcomes after switching HIV-positive patients with HIV viral load less than 100 copies from a PI-based regimen to a tenofovir, emtricitabine and efavirenz regimen
V Sivaraj1, B Connolly1, M-Y Tung2 and P Key1
1Darent Valley Hospital, Dartford, UK and 2Kent Community Health NHS Trust, Canterbury, UK

P163 Early experience of rilpivirine use in a medium-sized HIV cohort
R Taylor, A Darley and A Jayasuriya
Nottingham University Hospitals NHS Trust, Nottingham, UK